News|Articles|November 4, 2024
Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays
Author(s)Catalent
Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
EMA Calls New EU Pharma Legislation Most Significant in Two Decades
2
FDA’s CNPV Pilot Gives First Approval to Antibiotic for Pneumonia and Sinusitis
3
European Parliament Revamps Pharmaceutical Policy Framework
4
Tjoapack’s Advanced Packaging Expansion Aims to Meet Rising Demand
5
